title: Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
abstract: OBJECTIVE
  To compare the safety and efficacy of insulin aspart (IAsp), buffered regular insulin (BR), and insulin lispro administered by continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes.
  
  
  METHODS
  After completing a 4-week run-in period with BR, 146 adult patients with type 1 diabetes (with pretrial CSII experience) were randomly assigned (2:2:1) to CSII treatment with IAsp, BR, or lispro for 16 weeks in a multicenter, open-label, randomized, parallel-group study. Bolus insulin doses were administered 30 min before meals (BR) or immediately before meals (IAsp or lispro).
  
  
  RESULTS
  Treatment groups had similar baseline HbA(1c) (7.3% +/- 0.7 for IAsp, 7.5% +/- 0.8 for BR, and 7.3% +/- 0.7 for lispro). After 16 weeks of treatment, HbA1c values were relatively unchanged from baseline, and the mean changes in baseline HbA1c values were not significantly different between the three groups (0.00 +/- 0.51, 0.15 +/- 0.63, and 0.18 +/- 0.84 for the IAsp, BR, and lispro groups, respectively). The rates of hypoglycemic episodes (blood glucose <50 mg/dl) per patient per month were similar (3.7, 4.8, and 4.4 for the IAsp, BR, and lispro groups, respectively). Clogs/blockages in pumps or infusion sets were infrequent; most subjects (76, 83, and 75% in the IAsp, BR, and lispro groups, respectively) had < or = 1 clog or blockage per 4 weeks during the trial.
  
  
  CONCLUSIONS
  Insulin aspart in CSII was as efficacious and well tolerated as BR and lispro and is a suitable insulin for continuous subcutaneous insulin infusion using external pumps.
authors.affiliation: Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA. bbode@aol.com
authors.forename: Bruce
authors.initials: B
authors.lastname: Bode
authors.forename: Richard
authors.initials: R
authors.lastname: Weinstein
authors.forename: David
authors.initials: D
authors.lastname: Bell
authors.forename: Janet
authors.initials: J
authors.lastname: McGill
authors.forename: Daniel
authors.initials: D
authors.lastname: Nadeau
authors.forename: Philip
authors.initials: P
authors.lastname: Raskin
authors.forename: Jaime
authors.initials: J
authors.lastname: Davidson
authors.forename: Robert
authors.initials: R
authors.lastname: Henry
authors.forename: Won-Chin
authors.initials: WC
authors.lastname: Huang
authors.forename: Rickey R
authors.initials: RR
authors.lastname: Reinhardt
mesh_terms: D000328:Adult; D015992:Body Mass Index; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D061267:Insulin Aspart; D007332:Insulin Infusion Systems / Q000009:adverse effects; D061268:Insulin Lispro; D008297:Male; D012449:Safety
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D061267:Insulin Aspart; D061268:Insulin Lispro